Home
HelpMayo Test ID 5INHE Factor V Inhibitor Evaluation, Plasma
Ordering Guidance
This test is for factor V inhibitors only. If the presence or type of inhibitor is unknown, first order APROL / Prolonged Clot Time Profile, Plasma, except for patients with known hemophilia A or B. When screening studies are needed for patients with known hemophilia A or B, order 8INHE / Factor VIII Inhibitor Evaluation, Plasma; or 9 INHE / Factor IX Inhibitor Evaluation, Plasma; respectively.
Shipping Instructions
Send all vials in the same shipping container.
Necessary Information
Specimen Required
Specimen Type: Platelet-poor plasma
Patient Preparation:
1. Patient must not be receiving Coumadin (warfarin) or heparin therapy
2. Fasting preferred
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vials
Specimen Volume: 3 mL in 3 plastic vials, each containing 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma (1-2 mL per aliquot) into 3 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Useful For
Detection and quantitation of inhibitors against coagulation factor V
This test is not useful for the detection of a lupus-like circulating anticoagulant inhibitor, a nonspecific circulating anticoagulant, or other inhibitors that are not specific for coagulation factors.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 5INHT | FV Inhib Profile Tech Interp | No | Yes |
| FACTV | Coag Factor V Assay, P | Yes | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 5AINH | FV Inhib Profile Prof Interp | No | No |
| 5BETH | FV Bethesda Units, P | No | No |
| F5_IS | Factor V Inhib Scrn | No | No |
Testing Algorithm
Testing begins with coagulation factor V activity assay with dilutions to evaluate assay inhibition; if the factor V activity assay is normal or increased, then a technical interpretation will be provided.
If the factor V activity assay is decreased, then an inhibitor screen will be performed at an additional charge to look for specific factor V inhibition and a professional interpretation will be provided. If specific inhibition is apparent, the titer of the inhibitor will be determined.
Special Instructions
Method Name
FACTV, 5BETH, F5_IS: Optical Clot-Based
5INHT: Technical Interpretation
5AINH: Medical Interpretation
Reporting Name
Factor V Inhib Profile, PSpecimen Type
Plasma Na CitSpecimen Minimum Volume
2 Plastic vials, each containing1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma Na Cit | Frozen | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Factor V inhibitors can occur in patients with congenital factor V deficiency after transfusion of fresh frozen plasma, however, they more commonly occur spontaneously in previously healthy older patients who have no underlying diseases. Topical bovine thrombin or fibrin glue, which contain bovine thrombin and factor V, are commonly used in surgery for topical hemostasis and can result in development of anti-bovine thrombin/factor V inhibitors that cross-react with human thrombin and factor V. Other associations include antibiotics, transfusions, and malignancies.
Reference Values
FACTOR V ACTIVITY ASSAY
>1 month: 70-165%
<1 month: Normal, full-term and premature newborn infants may have mildly decreased levels (≥30% to 35%) that reach adult levels within 21 days postnatal.
*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing
FACTOR V INHIBITOR SCREEN:
Negative
GENERAL FACTOR BETHESDA UNITS:
≤0.5 Bethesda Units
Interpretation
Normally, there is no inhibitor (ie, negative result).
If the screening assays indicate the presence of an inhibitor, it will be quantitated and reported in Bethesda (or equivalent) units.
Cautions
Occasionally, a potent lupus-like anticoagulant may cause false-positive testing for a specific factor inhibitor (eg, factor VIII or IX).
Clinical Reference
1. Hoffman R, Benz Jr EJ, Silberstein LE, et al, eds: Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018
2. Kasper CK: Treatment of factor VIII inhibitors. Prog Hemost Thromb. 1989;9:57-86
3. Kottke-Marchant K, ed. Laboratory Hematology Practice. Wiley Blackwell Publishing; 2012
Method Description
This assay consists of measuring the difference in factor V activity (prothrombin time-based assay) before and after incubation of a mixture of normal plasma and patient's plasma for 1 hour at 37° C. For optimal sensitivity, the factor V value of the normal plasma is adjusted to approximately 20%, because the factor V assay is more sensitive in this area of the curve. In addition, an excess of patient's plasma will make the test more sensitive to small amounts of inhibitors.(Owen CA Jr, Bowie EJW, Thompson JH Jr: The Diagnosis of Bleeding Disorders. 2nd ed. Little, Brown and Company; 1975:143-145; Cielsa B. Defects of plasma clotting factors. In: Hematology in Practice. 3rd ed. FA Davis; 2019:chap 17)
If the inhibitor screen is positive for an inhibitor of factor V, the inhibitor will be quantitated by the Bethesda assays. In the Bethesda procedure, inhibitors are quantified by mixing equal volumes of serially diluted plasma with normal plasma. This mixture is incubated 2 hours at 37° C, and its factor V activity is measured and compared to a control run at the same time. The difference between the factor V activity of the patient's incubation mixture and that of the control is used to calculate titer. The residual factor V activity is converted to Bethesda units: 50% residual factor V is equal to 1 Bethesda unit.(Kasper CK, Aldedort LM, Counts RB, et al: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872; Cielsa B. Defects of plasma clotting factors. In: Hematology in Practice. 3rd ed. FA Davis; 2019:chap 17)
Day(s) Performed
Monday through Friday
Report Available
1 to 3 daysSpecimen Retention Time
7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
85390
85220
85335 (if appropriate)
85335 (if appropriate)
85390 (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| 5INHE | Factor V Inhib Profile, P | 96458-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 5INHT | FV Inhib Profile Tech Interp | 69049-5 |
| FACTV | Coag Factor V Assay, P | 3193-0 |